Skip to content

R&D at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
$163M+14.0%
IAR
Integra LifeSciencesIART
$23.5M-5.0%
ITG
Integer HoldingsITGR
$16.24M+14.4%
Glaukos logo
GlaukosGKOS
$44.15M+36.4%
HRO
HarrowHROW
$5.9M+94.8%
Bausch + Lomb logo
Bausch + LombBLCO
$101M+17.4%

Other financials

Income statement

See full
Revenue$93.5M+120%
Gross profit$68.9M+146%
Operating income$8.0M+114%
Net income$5.2M+110%
EPS (diluted)$0.10+109%

Balance sheet

See full
Cash & equivalents$131.9M-23.8%
Total debt$37.3M+1.7%
Total equity$352.4M+0.7%
Total assets$451.1M-1.4%

Cash flow

See full
Operating cash flow-$21.7M-278%
CapEx$443.0K-69.8%
Free cash flow-$22.1M-207%

Valuation

See full
Market cap$1.44B+77.9%
Enterprise value$1.35B+100.0%
P/S+2.1×

Profitability

See full
Gross margin76.9%+2.9pp
Operating margin-9.1%-3.5pp
Net margin-7.2%-3.0pp
FCF margin-19.6%+55.9pp

Returns & leverage

See full
Return on equity-6%-2.4pp
Debt / equity0.1×0.0×
Current ratio5.1×+0.3×

Where this comes from

Reported directly by Staar Surgical in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Staar Surgical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Staar Surgical's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Staar Surgical's R&D?
Staar Surgical (STAA) reported R&D of $9.93M in Q1 2026.
How has Staar Surgical's R&D changed year-over-year?
Staar Surgical's R&D decreased by 12.5% year-over-year, from $11.34M to $9.93M.
What is the long-term trend for Staar Surgical's R&D?
Over 4 years (2021 to 2025), Staar Surgical's R&D has grown at a 4.3% compound annual growth rate (CAGR), from $33.86M to $40.06M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.